相关实验视频

Updated: Jan 8, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在多线疗法后治疗EGFR突变肺腺素瘤的ivonescimab:一个病例报告

Xiaohua Pan¹, Jianya Zhang², Chao Ye²

¹School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.

Frontiers in oncology

|December 12, 2025

概括

一名患有EGFR突变肺癌的患者对IVONESCIMAB迅速反应,IVONESCIMAB是一种新的PD-1/VEGF-A双特异性抗体. 这突显了其在难以治疗的非小细胞肺癌 (NSCLC) 中克服耐药性的潜力.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
分子向疗法分子向疗法

背景情况:

先进的表皮生长因子受体 (EGFR) 突变肺癌通常会对标准疗法产生耐药性,包括氨酸激酶抑制剂 (TKI) 和化疗.
多线治疗失败在管理非小细胞肺癌 (NSCLC) 中是一个重大挑战,需要新的治疗策略.
瘤蛋白53 (TP53) 共同突变和腺状组织学与EGFR突变NSCLC的预后较差有关.

研究的目的:

报告一例成功使用IVONESCIMAB治疗的病例,该病例发生在患有EGFR突变肺腺癌的重度预治疗患者身上.
为了评估IVONESCIMAB的疗效和安全性,一种新的编程细胞死亡蛋白-1 (PD-1) /血管内皮生长因子-A (VEGF-A) 双特异性抗体,在克服治疗耐药性方面.
探索双重作用双特异抗体在耐火性NSCLC精密瘤学中的潜力.

主要方法:

一名51岁的男性患有晚期EGFR突变 (p.T790M和p.L858R) 肺腺素状癌的病例报告.
在多种先前的疗法失败后,使用IVONESCIMAB单一疗法,包括EGFR-TKIs,化疗,抗血管原剂和免疫检查点抑制剂.
使用成像 (部分响应 - PR) 评估治疗反应,并在六个治疗周期中评估毒性.

主要成果:

患者在两次IVONESCIMAB治疗后,实现了快速部分反应 (PR),肺位病变的显著回归.
反应持续了六个周期,与治疗相关的毒性最小.
尽管PD-L1表达低 (TPS 5%),TP53共突变和腺状组织学,但仍观察到有效性.

结论:

伊沃内西马布表明,它有可能成为多重耐药EGFR突变NSCLC患者的新疗法选择.
伊尼西马布的双重机制,针对PD-1和VEGF-A,可以通过调节免疫抑制和血管生成来克服耐药性.
进一步研究IVONESCIMAB和类似的双特异性抗体在高级NSCLC的精密瘤学中是有必要的.

关键词:

作为一个EGFR突变体.在NSCLCLC中,我们可以看到.状腺癌 (Adenosquamous Carcinoma) 是一种状腺癌.艾文斯基姆可能会出现.多线疗法是多线疗法.

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.